Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Serum Levels of Infliximab and Anti-Infliximab Anti-bodies in Brazilian Patients with Crohn's Disease

Full text
Author(s):
Miani Gomes, Luis Eduardo [1] ; Ramos da Silva, Francesca Aparecida [1] ; Pascoal, Livia Bitencourt [1] ; Ricci, Renato Lazarin [1] ; Nogueira, Guilherme [2] ; Camargo, Michel Gardere [1] ; Setsuko Ayrizono, Maria de Lourdes [1] ; Fagundes, Joao Jose [1] ; Leal, Raquel Franco [1]
Total Authors: 9
Affiliation:
[1] Univ Estadual Campinas UNICAMP, Fac Ciencias Med, Lab Invest Doencas Inflamatorias Intestinais, Serv Coloproctol, Campinas, SP - Brazil
[2] Univ Estadual Campinas UNICAMP, Lab Sinalizacao Celular, Campinas, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: Clinics; v. 74, 2019.
Web of Science Citations: 2
Abstract

OBJECTIVES: The aim of this study was to evaluate the quantitative serum level of infliximab (IFX) as well as the detection of anti-infliximab antibodies (ATIs) in patients with Crohn's disease (CD). METHOD: Forty patients with CD under treatment at a tertiary center in southeastern Brazil were evaluated. Their use of infliximab was continuous and regular. We analyzed and compared the differences in the IFX and ATI levels between the patients with active CD (CDA) and those with CD in remission (CDR). RESULTS: There was no difference in the IFX level between the CDA and CDR groups (p>0.05). Eighty percent of all patients had IFX levels above the therapeutic concentration (6-10 mu g/mL). Two (9%) of the 22 patients with active disease and four (22.2%) of the 18 patients in remission had undetectable levels of IFX. Four (66.6%) of the six patients with undetectable levels of IFX had positive ATI levels; three of these patients were in remission, and one had active disease. In addition, the other two patients with undetectable levels of IFX presented ATI levels close to positivity (2.7 and 2.8 AU/ml). None of the patients with therapeutic or supratherapeutic IFX levels had positive ATI levels. CONCLUSIONS: The undetectable levels of IFX correlated with the detection of ATIs, which was independent of disease activity. Immunogenicity was not the main factor for the loss of response to IFX in our study, and the majority of patients in both groups (CDA and CDR) had supratherapeutic levels of IFX. (AU)

FAPESP's process: 17/21453-4 - Evaluation of infliximabe through levels and detection of anti-infliximabe antibodies in Crohn's Disease patients
Grantee:Renato Lazarin Ricci
Support Opportunities: Scholarships in Brazil - Scientific Initiation